COVID-19 Preclinical Disease Modeling and Vaccine Development
Developing effective therapies and vaccines against COVID-19 requires translational preclinical animal models.
Our webinar presented by Dr. Terina Martinez, Field Application Scientist at Taconic Biosciences, presents a high-level overview of the animal models suitable for COVID-19 research along with a deeper dive into specific mouse models for studies of SARS-CoV-2 disease pathogenesis and screening of therapeutics and vaccines.
Watch to learn about:
- Newly available transgenic mice expressing human ACE2 which are susceptible to infection by SARS-CoV-2 infection and subsequent development of severe disease
- GEMs available to interrogate the role of ACE2 in acute respiratory distress syndrome, the role of APOE in COVID-19 disease severity, and mechanisms of viral entry
- How to use wild type inbred strains in combination with mouse-adapted virus
- Special biosecurity concerns for housing and handling of mouse models susceptible to SARS-CoV-2
Dr. Terina Martinez
Field Applications Scientist | Taconic Biosciences
Terina has deep expertise in target validation, animal model generation and characterization, and optimization of preclinical study design. She earned her doctorate degree from the University of Texas Southwestern Medical Center and did postdoctoral work at the University of Pittsburgh focusing on mechanisms of neuroinflammation and the role of the immune system in neurodegeneration. Prior to joining Taconic, Terina was with The Michael J. Fox Foundation for Parkinson’s Research, where she served as Senior Associate Director for Research Programs and led the Foundation’s Preclinical Tools and Animal Models, Inflammation, and Emerging Targets programs.